Sagimet Biosciences Gains Momentum with Nasdaq Move and Investor Conference Spotlight

San Mateo, Tuesday, 23 June 2026.
Sagimet Biosciences is making strategic strides as it joins the S&P Biotechnology Select Industry Index and secures a Nasdaq inducement grant. With its lead drug, denifanstat, showing breakthrough potential in treating acne and MASH, the company’s stock surged 40% this year. Investors are buzzing after positive Phase 3 acne trial results in China, fueling optimism for a U.S. trial later in 2026. This dual focus on metabolic and viral diseases positions Sagimet as a key player in biotech, attracting both retail and institutional interest.